Open AccessTetrabenazine: Spotlight on Drug Review
Author(s) -
Navneet Kaur,
Puneet Kumar,
Sumit Jamwal,
Rahul Deshmukh,
Vinod Gauttam
Publication year - 2016
Publication title -
annals of neurosciences
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.545
H-Index - 19
eISSN - 0976-3260
pISSN - 0972-7531
DOI - 10.1159/000449184
Subject(s) - tetrabenazine , tardive dyskinesia , chorea , tics , medicine , dystonia , drug , pharmacology , movement disorders , clinical trial , psychiatry , tourette syndrome , disease , dopamine , schizophrenia (object oriented programming)
Tetrabenazine (TBZ) is the only US Food and Drug Administration-approved drug for the treatment of chorea related to Huntington's disease and other hyperkinetic disorders. TBZ was first synthesized in 1950, and was then used for the treatment of psychosis. But later its potential in treating hyperkinetic disorders was proved by its ability to block vesicular monoamine transporters 2 and deplete monoamine stores. There is still lack of awareness about the therapeutic potential of this drug.